Table 3

Frequency distribution of the polymorphic genotypes among cases and two control groups

Group one consists of patients with no cancer from any biopsy and group two consists of patients with no cancer from two or more prostate biopsies.

GenotypeNumber of cases (n = 483)Number of ControlsP
Control group 1 (n = 548)PControl group 2 (n = 256)
SRD5A2
VV250 (51.8%)257 (46.9%)122 (47.7%)
V/L194 (40.2%)238 (43.4%)111 (36.4%)
L/L39 (8.1%)53 (9.7%)0.2723 (9.0%)0.57
CYP17
A1/A1178 (36.9%)195 (35.6%)89 (34.8%)
A1/A2228 (47.2%)254 (46.3%)121 (47.3%)
A2/A277 (15.9%)99 (18.1%)0.6646 (17.9%)0.74
CYP3A4
WW411 (85.1%)469 (85.6%)216 (84.4%)
WV51 (10.6%)55 (10.0%)28 (10.9%)
VV21 (4.3%)24 (4.4%)0.9612 (4.7%)0.96
PSA
AA159 (32.9%)164 (29.9%)75 (29.3%)
AG205 (42.5%)239 (43.6%)115 (44.9%)
GG119 (24.6%)145 (26.5%)0.5666 (25.8%)0.60
VDR
bb114 (23.6%)130 (23.7%)57 (22.3%)
Bb174 (36.0%)203 (37.0%)93 (36.3%)
BB195 (40.4%)215 (39.3%)0.92106 (41.4%)0.92
GST-T1
 090 (18.6%)127 (23.2%)70 (27.3%)
 1393 (81.4%)421 (76.8%)0.07186 (72.7%)0.006
GST-M1
 0235 (48.6%)266 (48.5%)124 (48.4%)
 1248 (51.4%)282 (51.5%)0.57132 (51.6%)0.77
GST-P1
IL/IL227 (47.0%)286 (52.2%)130 (50.8%)
IL/V225 (46.6%)232 (42.3%)111 (43.4%)
VV31 (6.4%)30 (5.5%)0.2415 (5.8%)0.62
IGF-I
No 19 allele64 (13.3%)103 (18.8%)0.0553 (20.7%)0.02
One 19 allele230 (47.6%)253 (46.2%)120 (46.9%)
Two 19 alleles189 (39.1%)192 (35.0%)83 (32.4%)
IGFBP-3
AA135 (28.0%)145 (26.5%)74 (28.9%)
AC233 (48.2%)274 (50.0%)125 (48.8%)
CC115 (23.8%)129 (23.5%)0.8357 (22.3%)0.89
AR
 ≤18 units421 (87.2%)476 (86.9%)217 (84.8%)
 >18 units62 (12.8%)72 (13.1%)0.8939 (15.2%)0.37